FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W984482755> ?p ?o ?g. }

• W984482755 endingPage "40" @default.
• W984482755 startingPage "339" @default.
• W984482755 abstract "Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine have been associated with suicide attempts and violent acts.1,2 We report 3 female patients with refractory panic disorder who, during fluvoxamine treatment, impulsively hit family members.Case 1A 32-year-old woman experienced abrupt onsets of palpitations and shortness of breath during the last 9 years. She could not enter reinforced concrete buildings or ride on elevators because she had a fear of closed spaces, and she could not go out alone because of anxiety regarding her next attack. This concern was associated with the development of avoidant behaviour. She was diagnosed with panic disorder with agoraphobia and was first treated, unsatisfactorily, with 25–75 mg of clomipramine and several anxiolytics daily because of anticholinergic side effects.The woman gradually became depressed and was administered 20 mg of fluoxetine and 5 mg of bromazepam daily for 2 months; her medication was then changed to 40 mg of fluoxetine and 1.5 mg of lorazepam daily for about 6 months. However, this medication regimen did not completely suppress her panic attacks or ameliorate her depressive symptoms. The woman was then prescribed 50 mg of fluvoxamine and 2 mg of ethyl loflazepate daily for 1 week, and the fluvoxamine dosage was increased weekly to 150 mg/day. Six weeks after the initiation of fluvoxamine, the woman became irritable and aggressive, and she expressed impulsive violence during disagreements with her husband and mother. Two days after the fluvoxamine dosage was decreased by half (to 75 mg/day) and coadministered with 20 mg of fluoxetine, the abnormal behaviour stopped.Case 2A 29-year-old woman began to experience sudden palpitations and shortness of breath when she cleared snow from the front of her house 3 years previously. She sometimes had to be taken to hospital by ambulance when she had a panic attack and would not go out alone because of her fear of the next attack. She was diagnosed with panic disorder with agoraphobia, which was unsatisfactorily treated with 50–75 mg of amoxapine, 25 mg of trazodone and 2–3 mg of ethyl loflazepate, daily, for 6 months. She gradually became depressed and was prescribed a regimen of fluvoxamine (up to 150 mg/day) with coadministration of amoxapine and ethyl loflazepate. After 2 months of treatment, her panic attacks had been, to a large extent, alleviated. She could even ride on the subway alone. However, she gradually began to exhibit signs of irritability and nervousness; she became easily excited when she argued with her husband and was impulsively violent with him. The woman was admitted to a psychiatric hospital for 1 week. Fluvoxamine was discontinued, and 75 mg of amoxapine, 200 mg of sulpiride, 3 mg of ethyl loflazepate and 5 mg of bromazepam was initiated. With this change, the woman's irritability was alleviated and the violence stopped.Case 3A 28-year-old divorced woman with a 10-year history of episodic obsessive–compulsive disorder (OCD) had been experiencing palpitations and shortness of breath since she was 23 years old. A recurrent fear of an explosion forced her, when outside, to walk in the centre of the street. She was diagnosed with OCD and panic disorder with agoraphobia, which was unsatisfactorily treated with 100 mg of sulpiride, 20 mg of amoxapine and 0.8 mg of alprazolam or with 50 mg of dosulepin, 10 mg of prazepam and 2 mg of ethyl loflazepate for about 6 months. When the woman became depressed, she was given 50 mg of fluvoxamine daily, with coadministration of 30 mg of amoxapine and 2 mg of ethyl loflazepate. Fluvoxamine dosage was increased weekly up to a maximum of 150 mg/day. After a month on this regimen, she exhibited signs of irritability and aggressive behaviour, expressing impulsive violence toward her mother. Fluvoxamine treatment was discontinued; sulpiride, mianserin and bromazepam were initiated, and the woman's abnormal behaviour ceased.DiscussionAll 3 cases of refractory panic disorder were associated with depressive symptoms. Tricyclic antidepressant treatment was unsatisfactory because of anticholinergic side effects, but it ameliorated the patients' symptoms to a certain extent. When fluvoxamine was coadministered with ethyl loflazepate or small doses of amoxapine for 1–2 months, patients exhibited signs of irritability and impulsive aggressive behaviour. No other antidepressants used in these cases induced such behaviour. Prompt discontinuation of fluvoxamine in cases 2 and 3 and the reduction of fluvoxamine by half and coadministration of fluoxetine in case 1 reversed the symptoms. In case 1, fluoxetine treatment did not elicit the aggressive behaviour that treatment with fluvoxamine did.Serotonergic abnormalities have been proposed as a neurobiological basis for aggression and impulsivity.3 The aggressive behaviour in these cases may be related to the fact that fluvoxamine is a more selective serotonin reuptake inhibitor than fluoxetine.4 Some reports have described the beneficial effect of SSRIs on impulsivity and aggression.5,6 However, we wish to draw attention to the emergence of paradoxical effects such as impulsivity and aggressive behaviour induced by fluvoxamine treatment.Fumihiko Okada, MDSapporo, JapanKiyoko Okajima, MDSapporo, Japan" @default.
• W984482755 created "2016-06-24" @default.
• W984482755 creator A5023039709 @default.
• W984482755 creator A5088717066 @default.
• W984482755 date "2001-09-01" @default.
• W984482755 modified "2023-09-23" @default.
• W984482755 title "Violent acts associated with fluvoxamine treatment." @default.
• W984482755 cites W2043072732 @default.
• W984482755 cites W2086733302 @default.
• W984482755 cites W2151584332 @default.
• W984482755 cites W2268179868 @default.
• W984482755 cites W2273087713 @default.
• W984482755 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/167189" @default.
• W984482755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11590975" @default.
• W984482755 hasPublicationYear "2001" @default.
• W984482755 type Work @default.
• W984482755 sameAs 984482755 @default.
• W984482755 citedByCount "4" @default.
• W984482755 countsByYear W9844827552015 @default.
• W984482755 countsByYear W9844827552016 @default.
• W984482755 crossrefType "journal-article" @default.
• W984482755 hasAuthorship W984482755A5023039709 @default.
• W984482755 hasAuthorship W984482755A5088717066 @default.
• W984482755 hasConcept C118552586 @default.
• W984482755 hasConcept C126322002 @default.
• W984482755 hasConcept C15744967 @default.
• W984482755 hasConcept C170493617 @default.
• W984482755 hasConcept C2775864247 @default.
• W984482755 hasConcept C2776134451 @default.
• W984482755 hasConcept C2777196872 @default.
• W984482755 hasConcept C2777529043 @default.
• W984482755 hasConcept C2778678127 @default.
• W984482755 hasConcept C2779177272 @default.
• W984482755 hasConcept C2779305415 @default.
• W984482755 hasConcept C2779910183 @default.
• W984482755 hasConcept C2780712732 @default.
• W984482755 hasConcept C31487548 @default.
• W984482755 hasConcept C42219234 @default.
• W984482755 hasConcept C558461103 @default.
• W984482755 hasConcept C71924100 @default.
• W984482755 hasConceptScore W984482755C118552586 @default.
• W984482755 hasConceptScore W984482755C126322002 @default.
• W984482755 hasConceptScore W984482755C15744967 @default.
• W984482755 hasConceptScore W984482755C170493617 @default.
• W984482755 hasConceptScore W984482755C2775864247 @default.
• W984482755 hasConceptScore W984482755C2776134451 @default.
• W984482755 hasConceptScore W984482755C2777196872 @default.
• W984482755 hasConceptScore W984482755C2777529043 @default.
• W984482755 hasConceptScore W984482755C2778678127 @default.
• W984482755 hasConceptScore W984482755C2779177272 @default.
• W984482755 hasConceptScore W984482755C2779305415 @default.
• W984482755 hasConceptScore W984482755C2779910183 @default.
• W984482755 hasConceptScore W984482755C2780712732 @default.
• W984482755 hasConceptScore W984482755C31487548 @default.
• W984482755 hasConceptScore W984482755C42219234 @default.
• W984482755 hasConceptScore W984482755C558461103 @default.
• W984482755 hasConceptScore W984482755C71924100 @default.
• W984482755 hasIssue "4" @default.
• W984482755 hasLocation W9844827551 @default.
• W984482755 hasOpenAccess W984482755 @default.
• W984482755 hasPrimaryLocation W9844827551 @default.
• W984482755 hasRelatedWork W1560455169 @default.
• W984482755 hasRelatedWork W1977915868 @default.
• W984482755 hasRelatedWork W1988030263 @default.
• W984482755 hasRelatedWork W1990519761 @default.
• W984482755 hasRelatedWork W2031669980 @default.
• W984482755 hasRelatedWork W2070245218 @default.
• W984482755 hasRelatedWork W2101149615 @default.
• W984482755 hasRelatedWork W2249026036 @default.
• W984482755 hasRelatedWork W2479427747 @default.
• W984482755 hasRelatedWork W984482755 @default.
• W984482755 hasVolume "26" @default.
• W984482755 isParatext "false" @default.
• W984482755 isRetracted "false" @default.
• W984482755 magId "984482755" @default.
• W984482755 workType "article" @default.